Lena Friberg

Lena Friberg was promoted to Professor of Pharmacometrics in 2014 and is since 2021 employed as Professor of Pharmacokinetics and Pharmacodynamics. Her research focuses on translation and dose optimization within oncology and infectious diseases, by advancing concepts for interpretation and integration of in vitro, in vivo and clinical data through PKPD-modelling. Developed methodology facilitates transition between drug development stages while considering both desired and adverse effects.

Lena is since 2021 employed as Professor of Pharmacokinetics and Pharmacodynamics (Professor of Pharmacometrics 2014-2021). She obtained her PhD in 2003 and in 2007 she became Docent (Associate professor). During 2003-2008 she was supported by a personal grant from Knut & Alice Wallenberg foundation for a postdoc at the University of Queensland, Australia, and as a researcher at Uppsala University.

The research focuses on developing approaches for predictive translation of effects from preclinical data to patients, both for desired outcomes and adverse events. Important achievements include frameworks to be applied for optimized dosing strategies of new and available drugs in the areas of oncology and infection.

Lena has published >190 peer-reviewed research articles and has an h-index of 56. She has been main (co) supervisor of 12 (10) students to PhD degree and is currently supervising 9 (4) PhD students, in addition to mentoring Postdocs and early researchers. She holds competitive grants from Swedish Research Council, Swedish Cancer Society, Swedish Childhood Cancer Fund, Innovative Medicines Initiative (EU-IMI2) and Marie Skłodowska-Curie Innovative Training Networks (ITN). Lena has received the Giorgio Segré Prize from EUFEPS for “distinct research in the Pharmacokinetic-Pharmacodynamic area”, the Innovation award from ISoP and been appointed ISoP fellow and Key Scientist" by Vinnova/BioSweden. She is since 2023 the Head of Department of Pharmacy.